Inadequate Management of Opioid-induced Constipation in European Cancer Pain Patients: Results of a Real-world, Multicentre, Observational Study ("E-StOIC")

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2024 Oct 4

PMID 39367106

Authors

Andrew Davies

Norah Fagan

Jesus Gonzalez-Barboteo

Cosimo Chelazzi

Guillaume Economos

Frank Elsner

Charlotte Leach

Ragnhild E Monsen

Wendy H Oldenmenger

Constanze Remi

Marieke van den Beuken-van Everdingen

Marion Wustefeld

Affiliations

Soon will be listed here.

Abstract

Purpose: The objectives of the study were to determine the prevalence of (uncontrolled) OIC, relevant medications / interventions employed by healthcare professionals, and the additional strategies utilised by patients, amongst European patients with cancer pain.

Methods: This study was a prospective observational study conducted at 24 research sites in ten European countries. Cancer patients receiving opioid analgesics for at least a week were recruited, and asked to complete a questionnaire including background information, single question (Are you constipated?), Rome IV diagnostic criteria for OIC, Bowel Function Index (BFI), and Patient Assessment of Constipation Quality of Life questionnaire (PAC-QOL). Participants were characterised as having / not having OIC on the basis of the Rome IV diagnostic criteria.

Results: 1200 participants completed the study. 59.5% met the Rome IV diagnostic criteria for OIC: only 61.5% that met these criteria self-reported constipation. 72% participants were prescribed a regular conventional laxative / peripherally acting mu-opioid receptor antagonist (PAMORA). However, only 66% took their prescribed laxatives every day. Many participants had utilised other strategies / interventions to manage their OIC. Furthermore, 27% had needed to use suppositories, 26.5% had needed to use an enema, and 8% had had a manual evacuation. The use of PAMORAs, and other novel effective medications, was relatively uncommon.

Conclusion: The results of this study suggest that management in Europe is often inadequate, and this undoubtedly relates to a combination of inadequate assessment, inappropriate treatment, and inadequate reassessment.

References

Lindberg G, Hamid S, Malfertheiner P, Thomsen O, Bustos Fernandez L, Garisch J . World Gastroenterology Organisation global guideline: Constipation--a global perspective. J Clin Gastroenterol. 2011; 45(6):483-7. DOI: 10.1097/MCG.0b013e31820fb914. View

Walter S, Hallbook O, Gotthard R, Bergmark M, Sjodahl R . A population-based study on bowel habits in a Swedish community: prevalence of faecal incontinence and constipation. Scand J Gastroenterol. 2002; 37(8):911-6. DOI: 10.1080/003655202760230865. View

Davies A, Leach C, Caponero R, Dickman A, Fuchs D, Paice J . MASCC recommendations on the management of constipation in patients with advanced cancer. Support Care Cancer. 2019; 28(1):23-33. DOI: 10.1007/s00520-019-05016-4. View

Camilleri M, Drossman D, Becker G, Webster L, Davies A, Mawe G . Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014; 26(10):1386-95. PMC: 4358801. DOI: 10.1111/nmo.12417. View

Davies A, Leach C, Butler C, Gregory A, Henshaw S, Minton O . Opioid-induced constipation in patients with cancer: a "real-world," multicentre, observational study of diagnostic criteria and clinical features. Pain. 2020; 162(1):309-318. DOI: 10.1097/j.pain.0000000000002024. View

Crockett S, Greer K, Heidelbaugh J, Falck-Ytter Y, Hanson B, Sultan S . American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2018; 156(1):218-226. DOI: 10.1053/j.gastro.2018.07.016. View

Dhingra L, Shuk E, Grossman B, Strada A, Wald E, Portenoy A . A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med. 2012; 27(5):447-56. DOI: 10.1177/0269216312450358. View

Sondergaard J, Nordahl Christensen H, Ibsen R, Jarbol D, Kjellberg J . Healthcare resource use and costs of opioid-induced constipation among non-cancer and cancer patients on opioid therapy: A nationwide register-based cohort study in Denmark. Scand J Pain. 2017; 15:83-90. DOI: 10.1016/j.sjpain.2017.01.006. View

Fine P, Chen Y, Wittbrodt E, Datto C . Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer pain patients receiving continuous opioid therapy. Support Care Cancer. 2018; 27(2):687-696. DOI: 10.1007/s00520-018-4366-z. View

10.

Swarm R, Paice J, Anghelescu D, Are M, Bruce J, Buga S . Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(8):977-1007. DOI: 10.6004/jnccn.2019.0038. View

11.

Skollerud L, Fredheim O, Svendsen K, Skurtveit S, Borchgrevink P . Laxative prescriptions to cancer outpatients receiving opioids: a study from the Norwegian prescription database. Support Care Cancer. 2012; 21(1):67-73. DOI: 10.1007/s00520-012-1494-8. View

12.

Rojas-Concha L, Hansen M, Adsersen M, Petersen M, Groenvold M . Implementation of clinical guidelines in specialized palliative care-results from a national improvement project: A national register-based study. Palliat Med. 2023; 37(5):749-759. DOI: 10.1177/02692163231155977. View

13.

Zeppetella G . How do terminally ill patients at home take their medication?. Palliat Med. 2000; 13(6):469-75. DOI: 10.1191/026921699675653923. View

14.

Clark K, Rowett D, Robinson M, Currow D . Uptake of methylnaltrexone in Australian patients with opioid-induced constipation: a review of the number of prescriptions presented in the first 12 months of subsidisation. BMJ Support Palliat Care. 2014; 3(1):98-102. DOI: 10.1136/bmjspcare-2012-000284. View

15.

Sera L, McPherson M . Management of Opioid-Induced Constipation in Hospice Patients. Am J Hosp Palliat Care. 2017; 35(2):330-335. DOI: 10.1177/1049909117705379. View

16.

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

17.

Rentz A, Yu R, Muller-Lissner S, Leyendecker P . Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009; 12(4):371-83. DOI: 10.3111/13696990903430481. View

18.

Marquis P, de la Loge C, Dubois D, McDermott A, Chassany O . Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005; 40(5):540-51. DOI: 10.1080/00365520510012208. View

19.

Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H . Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001; 19(9):2542-54. DOI: 10.1200/JCO.2001.19.9.2542. View

20.

Laugsand E, Jakobsen G, Kaasa S, Klepstad P . Inadequate symptom control in advanced cancer patients across Europe. Support Care Cancer. 2010; 19(12):2005-14. PMC: 3204099. DOI: 10.1007/s00520-010-1051-2. View